EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

New and emerging treatments for PBC-related pruritus

Sarah L Anderson

Drugs in Context · 21.05.2026 · 15 · 1

DOI: 10.7573/dic.2025-12-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs in Context, online erschienen am 21.05.2026. Verfasst von Sarah L Anderson. Beteiligte Einrichtung: PeerView Institute for Medical Education, New York, NY, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pruritus is an early and often debilitating symptom of primary biliary cholangitis (PBC), significantly impairing quality of life through fatigue, sleep disturbance, anxiety and social withdrawal. Traditional management relies on a stepwise approach, with bile acid sequestrants as first-line therapy and rifampin, naltrexone, or sertraline for refractory cases, but these agents often provide incomplete relief and are limited by tolerability and drug–drug interaction concerns. Advances in understanding the mechanisms of cholestatic itch have expanded treatment options to include peroxisome proliferator-activated receptor (PPAR) agonists, such as seladelpar, elafibranor and bezafibrate that uniquely offer both antipruritic effects and improvement in biochemical markers of disease activity. Therapies targeting specific pruritogenic pathways now include ileal bile acid transporter (IBAT) inhibitors, one of which is now approved specifically for PBC-related pruritus, as well as κ-opioid receptor agonists, MrgprX4 antagonists, and autotaxin inhibitors. Optimal management integrates pharmacological therapy with supportive strategies, including skin care, lifestyle modifications and psychosocial support tailored to the individual patient’s disease activity, symptom severity, and comorbidities. By addressing both the biological and experiential dimensions of pruritus, this comprehensive framework enables clinicians to improve symptom control and enhance overall quality of life for patients living with PBC. Emerging therapies and a mechanism-informed treatment approach offer promise for more effective, individualized care in this challenging clinical context. Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-new-and-emerging-treatments-for-pbc-related-pruritus

Schlagwörter

Stichwörter der Autor:innen

primary biliary cholangitispruritustreatment

Autor:innen und Institutionen

  • PeerView Institute for Medical Education, New York, NY, USA.

Zitieren

APA

Anderson, S. L. (2026). New and emerging treatments for PBC-related pruritus. Drugs in Context, 15, 1. https://doi.org/10.7573/dic.2025-12-3

Vancouver

Anderson SL. New and emerging treatments for PBC-related pruritus. Drugs in Context. 2026;15:1. doi:10.7573/dic.2025-12-3

BibTeX
@article{Anderson2026,
  author = {Anderson, Sarah L},
  title = {New and emerging treatments for PBC-related pruritus},
  journal = {Drugs in Context},
  year = {2026},
  volume = {15},
  pages = {1},
  doi = {10.7573/dic.2025-12-3}
}
Kostenlos starten →